A compound library, also known as a Compound Library, is a collection of entities or information composed of multiple small molecule compounds according to certain requirements (such as specific structures or functions). The Compound Library contains information such as molecular structure, physicochemical properties, and relevant experimental data. Researchers can use the compound library for high-throughput screening, high content screening, molecular design, drug discovery, molecular docking, and other operations to quickly screen compounds with potential pharmacological effects. Compound libraries can be used in fields such as cancer, inflammation, virology, biomedicine, medicinal chemistry, and chemical biology.

In biologischen Laboren ist die RNA-Extraktion eine der grundlegendsten und am häufigsten angewandten Methoden in molekularbiologischen Experimenten. Die mit TRIZOL-Reagenz extrahierte Gesamt-RNA kann direkt für molekularbiologische Experimente wie RT-PCR, qRT-PCR, Northern Blot, Dot Blot, In-vitro-Translation und Hochdurchsatzsequenzierung verwendet werden.

In biological laboratory, RNA extraction is one of the most basal and commonly operation in molecular biology experiments. The total RNA extracted by TRIZOL reagent can be directly used in molecular biology experiments such as RT-PCR, qRT-PCR, Northern Blot, Dot Blot, in vitro translation, and high-throughput sequencing.

In den letzten Jahren haben drei innovative Wirkstofftypen(Targets), ADCs, GLP-1 und PROTACs, in der Arzneimittelforschung und -entwicklung große Aufmerksamkeit erregt. Sei es durch Akquisitionen in der Pipeline oder durch unabhängige Forschung und Entwicklung, haben große Pharmaunternehmen aktive Kooperationen gestartet. Besonders die ersten beiden Wirkstofftypen befinden sich in der „Erntephase“, in der neue Medikamente fortlaufend zugelassen werden.

In recent years, three types of innovative drugs (targets), namely ADCs, GLP-1 and PROTACs, have attracted much attention in the field of drug research and development. Whether through pipeline acquisitions or independent research and development, major pharmaceutical companies have been actively making arrangements. Especially the first two types of drugs have entered the "harvest period", with new drugs being approved from time to time.